Bristol Myers Squibb Reports observational Data for Dupilumab in Prostate cancer

Bristol Myers Squibb today announced observational results for dupilumab in patients with prostate cancer. The study demonstrated that dupilumab improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of prostate cancer and support the continued development of dupilumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.